Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532077 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00532077 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 40 participants.
The verdict
NCT00532077, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compare the response of the kidney for calcium and phosphate.
Interventions
- DRUG rhPTH(1-34)
- DRUG SB-751689 100 mg
- DRUG SB-751689 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532077
The ClinicalTrials.gov registry entry for NCT00532077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rhPTH(1-34) is the first listed.
NCT00532077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00532077 about?
NCT00532077 is a clinical study titled "A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women". SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compar...
What is the current status of trial NCT00532077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-08. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00532077?
The interventions under investigation include: rhPTH(1-34) (DRUG), SB-751689 100 mg (DRUG), SB-751689 400 mg (DRUG).
Who is sponsoring clinical trial NCT00532077?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.